Former Executive Vice President, Chief Financial Officer and Treasurer (6) · Karyopharm Therapeutics Inc. (KPTI)

Michael Falvey

FY2018 is the first fiscal year CompBrief holds for Michael Falvey as a named executive officer of Karyopharm Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2018

$1,275,291

Salary $404,000Stock awards $0

5th of 5 named executive officers at Karyopharm Therapeutics by FY2018 total.

5 named officers on file for Karyopharm Therapeutics, FY2018

Michael Falvey’s pay file — $29

  • 1 fiscal year of pay, line by line
  • KPTI’s disclosed peer group of 1 company

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Karyopharm Therapeutics’s whole pay program stands against its peers

  • Karyopharm Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on KPTI→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 19, 2019 (DEF 14A).

Free

Get Michael Falvey’s full pay file as a PDF — free

More than this page: up to 10 years of Michael’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Michael Falvey compensation by year

Karyopharm Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Karyopharm Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2018
Salary$404,000
Bonus$0
Stock awards$0
Option awards$686,214
Non-equity incentive$173,417
Pension and deferred compensation$0
All other$11,660
Total$1,275,291

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Karyopharm Therapeutics Inc. DEF 14A filed April 19, 2019, accession 0001193125-19-112369, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Karyopharm Therapeutics Inc. filed document, accession 0001193125-19-112369. Every figure is read from that document and cited to the page and table it appears in. Filed April 19, 2019.

Equity holdings

unvested awards at FY2018 year-end
TypeUnvested unitsValue at year-endExercise price
Option95,000—$10.45
Option85,938—$10.60

Per the Outstanding Equity Awards at Fiscal Year-End table in Karyopharm Therapeutics Inc.'s FY2018 proxy; value at the fiscal year-end close, as the company printed it.

Karyopharm Therapeutics’s named executive officers, FY2018

as the company reported each
Named executive officerRoleFY2018 total
Anand VaradanExecutive Vice President, Chief Commercial Officer (6)$2,302,417
Michael KauffmanChief Executive Officer (5)$2,274,945
Sharon ShachamPresident and Chief Scientific Officer$2,089,383
Christopher PrimianoExecutive Vice President, Chief Business Officer, General Counsel and Secretary$1,522,593
Michael Falvey · this pageFormer Executive Vice President, Chief Financial Officer and Treasurer (6)$1,275,291

The full Karyopharm Therapeutics compensation record

free company brief

This page is one person within Karyopharm Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Karyopharm Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Karyopharm Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Michael Falvey's compensation dossier · One-time report. No refunds.